PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
暂无分享,去创建一个
G. Mills | G. Hortobagyi | F. Meric-Bernstam | A. Sahin | A. Lluch | A. González-Angulo | Shuying Liu | Huiqin Chen | J. Ferrer-Lozano | J. A. Barrera | O. Burgués | K. Stemke‐Hale
[1] D. Carrasco,et al. PIK3CA mutations in in situ and invasive breast carcinomas. , 2010, Cancer research.
[2] G. Mills,et al. PI3K pathway-directed therapeutic strategies in cancer. , 2010, Current opinion in investigational drugs.
[3] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[4] W. Woodward,et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] G. Hortobagyi,et al. Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes , 2009, Clinical Cancer Research.
[6] G. Mills,et al. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. , 2009, Cancer research.
[7] Funda Meric-Bernstam,et al. Targeting the mTOR signaling network for cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Zhi Hu,et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.
[9] F. Meric-Bernstam,et al. Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases , 2008, Cancer.
[10] G. Mills,et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. , 2007, Cancer cell.
[11] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[12] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[13] Annuska M Glas,et al. Gene expression profiles of primary breast tumors maintained in distant metastases , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[14] D. Merkel,et al. erbB-2 (HER-2) and Breast Cancer Progression , 2003, Applied immunohistochemistry & molecular morphology : AIMM.
[15] D. Larsimont,et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] A. Vincent-Salomon,et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process , 2002, Cancer.
[17] O. Stål,et al. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients , 2002, British Journal of Cancer.
[18] H. Moch,et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. , 2001, Journal of the National Cancer Institute.
[19] D. Larsimont,et al. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] C. Shimizu,et al. c‐erbB‐2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues , 2000, Journal of surgical oncology.
[21] J. Feldman,et al. Marked Intratumoral Heterogeneity of the Proto‐Oncogene Her‐2/neu Determined by Three Different Detection Systems , 1999, The breast journal.
[22] D. Allred,et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[23] Benjamin D. L. Li,et al. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer , 1994, Journal of surgical oncology.
[24] R. Kerbel. Growth dominance of the metastatic cancer cell: cellular and molecular aspects. , 1990, Advances in cancer research.
[25] M. Kraus,et al. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. , 1989, Oncogene.